English हिन्दी
Connect with us

Latest Science News

World welcomes roll-out of a Malaria vaccine; it is only partly effective, though

Published

on

World welcomes roll-out of a Malaria vaccine; it is only partly effective, though

The World Health Organisation (WHO) has welcomed a pilot project in Malawi, Africa, of administering a malaria vaccine to children below the age of 2 years, covering a total 3,60,000 children across three African countries — Malawi, Ghana and Kenya — to protect them from the mosquito-borne disease that causes 435,000 people global deaths each year.

The RTS,S/AS01 (trade name Mosquirix) is an injectible recombinant protein-based vaccine that acts against P. falciparum, the most prevalent malaria strain in Africa. It has been in development by GSK, the former GlaxoSmithKline, for more than 30 years.

Children under five years are at the greatest risk of death, with at least 250,000 children dying of the disease in Africa each year. Finding new weapons is crucial but making a malaria vaccine has proved challenging in the extreme. Surviving the disease does not provide lasting immunity. People who suffer numerous bouts in childhood become able to tolerate new infections, but if they leave the area for even a few years, their immunity wanes and a later infection can kill them.

The new vaccine has many weaknesses, pointed out a New York Times (NYT) report. It is inconvenient: A child must receive four injections before age 2, sometimes at intervals that do not match the routine vaccine schedules for most other diseases. And it is only partly effective. Testing in more than 10,000 African children from 2009 to 2014 showed that, even after four doses, the vaccine prevented only about 40 percent of detectable malaria infections.

The vaccine reduced the occurrence of severe malaria by about 30 percent, and the occurrence of severe anaemia — a complication that often kills children — by about 60 percent. It did not protect well against parasite strains that were poor genetic matches, raising a concern that, over time, parasites could evolve resistance to the vaccine as they have to drugs.

WHO’s Strategic Advisory Group of Experts will assess the results of each high-transmission season for at least three years, watching to see in particular whether parents bring in their children for all four doses and whether any rare but threatening side effects appear.

During earlier trials, some children developed high fevers and seizures soon after being immunized, but they recovered. A few children later developed life-threatening meningitis, but it was not clear that the vaccine was to blame, reported NYT.

If there is a substantial increase in overall survival rates among vaccinated children, the WHO may recommend rolling out the vaccine in more locations.

With India reducing malaria cases by 24% in 2017 over the previous year using conventional methods, such as to “test-treat-track” all cases and distributing free insecticide-treated bed nets in endemic areas, the vaccine is unlikely to be made part of India’s public health programme, said a report by The Hindustan Times (HT) quoting experts.

In the sharpest global reduction in malaria in a year, cases India fell from 1,087,285 cases in 2016 to 844,558 in 2017, according to the World Malaria Report 2018, HT reported.

“Defeating malaria demands high-impact country-led and owned approaches,” said Dr Poonam Khetrapal Singh, WHO regional director for South-East Asia Region (SEARO), where cases have halved in two years using conventional methods. “Between 2015 and 2017, the (SEARO) region reduced its estimated malaria caseload by 56%, from 25.5 million to 11.3 million, with cases presumed and confirmed decreasing by 25% and more than halving of deaths. Maldives and Sri Lanka remain malaria-free, while seven of the region’s nine malaria endemic countries, including India, set to have reduced case incidence by 40% by 2020,” said Khetrapal Singh.

The rest of the world, however, has not been performing as well. After a reduction in global malaria deaths by 62% and cases by 41% between 2000 and 2015, cases went up from 217 million in 2016 to 219 million in 2017, according to the World Malaria Report 2018.

With around 95% of the under-5 malaria deaths taking place in Africa, the benefits for a vaccine that protects children will be far greater there, say ministry officials.

“India has reduced malaria by scaling up a diagnostic testing, treatment and surveillance and ensuring an uninterrupted drug and diagnostics supply chain, training community workers to test all fever cases and provide medicines, and distributing medicated bed-nets for prevention. With cost-effective conventional methods working for India, the government is unlikely to invest in a vaccine as part of the public health programme,” an unnamed health ministry official told HT.

“India’s strategy is to wait and watch how the roll-out in the public health setting shapes up in Africa. If the learning from the Africa experience is good and the cost implications low the vaccination may mainstreamed in few years. It will anyway take two to three years can go to scale, by when several states in India would have anyway eliminated the disease,” said Pratik Kumar, country director, Malaria No More, an international not-for-profit that is working closely with the state government of Odisha, which reported a 80% decline in malaria cases and deaths in 2017 over the previous year.

India News

President Droupadi Murmu launches India’s first homegrown CAR T-cell therapy for cancer treatment

The gene-based therapy, which is developed by the IIT Bombay and Tata Memorial Centre, is being rolled out in India at about one-tenth of its price outside the country.

Published

on

President Droupadi Murmu on Thursday launched India’s first indigenously-developed CAR T-cell therapy, a gene-based therapy, for cancer treatment, hailing it as a breakthrough that provides new hope for humankind in the battle against the diseases.

Speaking at the launch event at the Indian Institute of Technology (IIT) Bombay, Murmu said the indigenous development of the CAR T-cell therapy was an example of the Make in India initiative.  

The gene-based therapy, which is developed by the IIT Bombay and Tata Memorial Centre, is being rolled out in India at about one-tenth of its price outside the country, as per the senior official.

In CAR T-cell therapy, a patient’s T-cells, which is a type of immune system cell or stem cell, are modified in the laboratory and inserted back into the patient to attack and destroy cancer cells after editing the stem cell.

The NexCAR19 CAR T-cell therapy, the country’s first Made in India CAR T-cell therapy, is expected to bring down the cost of treatment significantly.

During her speech, Murmu said that this therapy is considered a phenomenal advance in medical sciences. The development of this therapy is also an example of the Make in India initiative and speaks volumes about Indian scientists and physicians, she added.

The launch of India’s first gene therapy is a significant breakthrough in the battle against cancer. As this line of treatment, named CAR T-cell therapy, is accessible and affordable, it provides a new hope for the whole of humankind, President Murmu further added.

The Tata Memorial Centre director Sudeep Gupta said the CAR T-cell therapy was enormously expensive and out of the reach of an overwhelming majority of people.

Asserting that, he said NexCar19 needs to be custom manufactured for every patient under the most stringent conditions, but it has been rolled out at approximately one-tenth of the price at which it is available outside India.

The treatment costs approximately Rs 4 crore abroad against Rs 30 lakh in India, said IIT Bombay director Prof Subhasis Chaudhuri.

He further said that the low-cost CAR T-cell therapy was a huge achievement for the country and cancer patients, and places India firmly on the global map of cell and gene therapy.

Comparing the achievement of Chandrayaan-3 with CAR T-cell therapy, Chaudhuri asserted that CAR-T cell therapy heralds India’s entry into the cell and genetic engineering group.

The Tata Memorial Centre director Gupta said the treatment will help some 20,000 Indians every year, and its rollout is a milestone in the field of cancer care and genetic engineering.

He added the CAR T-cell was not only a scientific achievement of the highest order but also had immense practical application. NexCAR19 will save many, many lives and wipe many, many tears, he emphasised.

Continue Reading

India News

ISRO launches weather satellite INSAT-3DS to monitor Earth’s surface, oceans  

The Naughty Boy has now become a mature, obedient and disciplined boy like PSLV, and GSLV as they have become a very robust vehicle for ISRO, said Tomy Joseph.

Published

on

The Indian Space Research Organisation (ISRO) on Saturday launched the INSAT-3DS mission from Satish Dhawan Space Centre in Sriharikota at 5:35 pm to monitor the Earth’s surface, observe the ocean and analyse the environment through various essential meteorological perspectives.

In its mission, the Geosynchronous Satellite Launch Vehicle (GSLV) aimed to deploy the INSAT-3DS meteorological satellite into the Geosynchronous Transfer Orbit (GTO). Subsequent orbit-raising maneuvers will ensure that the satellite is positioned in a Geo-stationary Orbit.

After being positioned in GSO, it will provide information on diverse atmospheric conditions via vertical profiles. INSAT-3DS will manage data collection and dissemination from Data Collection Platforms (DCPs). The satellite will help in search and rescue services.

Congratulating the team, ISRO Chairman S Somanath expressed his happiness over the successful accomplishment of the mission GSLV-F14 INSAT-3DS. He further said that the spacecraft has been injected into a very good orbit. The space agency has also noted that the vehicle has performed very well.

The INSAT-3DS Mission Director, Tomy Joseph sarcastically remarked, saying the Naughty Boy has now become a mature, obedient and disciplined boy like PSLV, and GSLV as they have become a very robust vehicle for ISRO.

The Geosynchronous Satellite Launch Vehicle (GSLV) is a launch vehicle with a length of 51.7 meters and a liftoff mass of 420 tonnes. It consists of three stages, the first stage (GS1) is made up of a solid propellant motor with 139-ton propellant and four earth-storable propellant stages (L40) strapons. Each strapon carries 40 tons of liquid propellant.

The second stage (GS2) is also an earth-storable propellant stage that carries 40-ton propellant, and the third stage (GS3) is a cryogenic stage with a 15-ton propellant loading of liquid oxygen (LOX) and liquid hydrogen (LH2).

To protect the satellite during the atmospheric regime, it is covered by an Ogive payload fairing. The GSLV is versatile and can be used to launch various spacecraft capable of performing communications, navigation, earth resource surveys, and other proprietary missions.

The launch of INSAT-3DS was a follow-on mission of Third Generation Meteorological Satellite from Geostationary Orbit. According to ISRO, the GSLV-F14/INSAT-3DS mission has been fully funded by the Ministry of Earth Sciences (MoES) and designed for enhanced meteorological observations and monitoring of land and ocean surfaces for weather forecasting and disaster warning.

The satellite will augment the Meteorological services along with the presently operational INSAT-3D and INSAT-3DR satellites.

Notably, the services will be used by various departments of the MoES such as the India Meteorology Department (IMD), National Centre for Medium-Range Weather Forecasting (NCMRWF), Indian Institute of Tropical Meteorology (IITM), National Institute of Ocean Technology (NIOT), Indian National Center for Ocean Information Services (INCOIS) and various other agencies.

Continue Reading

India News

PM Modi says day not far when an Indian will land on moon in indigenously built spacecraft

PM Modi said a strong roadmap has been drawn till 2040 for the space sector. He made the announcement after flagging off the first Namo Bharat train on the 17 km stretch of the Delhi-Meerut Regional Rapid Transit system.

Published

on

PM Modi says day not far when an Indian will land on moon in indigenously built spacecraft

Prime minister Narendra Modi on Friday said the government has drawn up a roadmap for the development of space sector and the day is not far when an Indian will travel to the moon in an indigenously built spacecraft. PM Modi said India’s Gaganyaan will soon take Indian astronauts to space and the India wants to establish its own space station.

PM Modi said a strong roadmap has been drawn till 2040 for the space sector. He made the announcement after flagging off the first Namo Bharat train on the 17 km stretch of the Delhi-Meerut Regional Rapid Transit system.

PM Modi recalled the success of India’s moon mission Chandrayaan3  which had recently placed the country’s tricolour on the lunar surface. He said India of the 21st century is writing new chapters of progress and development for the landing on the moon has left the world awestruck.

PM Modi added with impeccable hosting of the G20 summit, today’s India has become the centre of attraction and curiosity for the world. He said today’s India wins more than 100 medals in the Asian Games.

PM Modi added today’s India launches 5G on its own strength and takes it to all corners of India. He further added todays India does the highest number of digital transactions. He said the Namo trains that were flagged off today were all made in India.

PM Modi set goals for the Indian Space Research Organisation (ISRO) by asking engineers and scientists to work towards setting up an Indian space staion by 2035 and sending an Indian astronaut to the lunar surface by 2040. PM Modi also asked the scientists to undertake interplanetary missions like the Venus orbiter and also attempt a landing on Mars. PM Modi further added the government has handed over festival gifts by reducing the gas cylinder price by Rs 500 for Ujjwala Yojana beneficiaries.  

Continue Reading

Trending

-->

© Copyright 2022 APNLIVE.com